- The FDA has approved a long-acting schizophrenia drug from Janssen, a unit of Johnson & Johnson (NYSE: JNJ)
- Previously known as paliperidone palmitate, Invega Hafyera is a twice-yearly injectable. It’s the first and only twice-yearly med for the condition.
- The new long-acting regime joins J&J’s existing one-month and three-month formulations, dubbed Invega Sustenna and Invega Trinza, respectively, plus a two-week injection known as Risperdal Consta.
- The FDA based its approval on the results from a 702-patient Phase 3 trial. In that study, investigators found that the six-month formulation’s performance held up with those already using the three-month injection to avoid relapse.
- Related content: Benzinga’s Full FDA Calendar.
- Price Action: JNJ shares are up 0.10% at $173.30 during the market session on the last check Wednesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.